<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00837954</url>
  </required_header>
  <id_info>
    <org_study_id>AAG-G-H-0803</org_study_id>
    <nct_id>NCT00837954</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate the Hemostatic Effect of Lyostypt® Versus Surgicel® in Arterial Bypass Anastomosis</brief_title>
  <acronym>COBBANA</acronym>
  <official_title>Randomized, Controlled, Prospective Trial to Evaluate the Hemostatic Effect of Lyostypt® Versus Surgicel® in Arterial Bypass Anastomosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aesculap AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aesculap AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to demonstrate that the bleeding time of suture holes after
      construction of arterial bypass anastomosis is shorter after treatment with Lyostypt® than
      with Surgicel®
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hemostasis in peripheral vascular surgery is made more difficult by the need for direct
      arterial and arterial graft suturing as well as by systemic anticoagulation to prevent
      thrombosis during periods of vascular occlusion. Polytetrafluorethylene (PTFE) is one of the
      most frequently used graft materials for vascular replacement or bypass in the case when no
      autologous venae are available (1). However, the insufficient elasticity of PTFE and its
      porosity promote the development of suture hole bleeding (2,3) which can cause considerable
      loss of blood and prolongation of operations (2).

      This study is designed to demonstrate the superiority of Lyostypt® to oxidized cellulose
      (Surgicel®) for hemostasis of suture hole bleeding in arterial bypass anastomoses after
      vascular reconstruction. Lyostypt® is an absorbable, wet stable collagen compress made of
      collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation
      of coagulation factor XII. Therefore collagen is very effective in hemostasis. Collagen is
      cell-friendly whereas other hemostats significantly disturb cell growth. Advantages of
      collagen fleece are fast induction of hemostasis, low tissue reaction and fast absorption
      (15). Furthermore, collagen was shown to be the best overall hemostatic agent in
      microvascular surgery. Authors concluded that collagen fleece establish faster hemostasis
      than oxidized cellulose and that it was resorbed faster than oxidized cellulose (15).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to hemostasis</measure>
    <time_frame>Minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Complications</measure>
    <time_frame>30 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Mortality</measure>
    <time_frame>30 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Rating of Study Device evaluated by Surgeon</measure>
    <time_frame>intraoperatively</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Peripheral Vascular Diseases</condition>
  <condition>Hemostasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>distal Anastomosis Lyostypt®, proximal Anastomosis Surgicel®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>distal Anastomosis Surgicel®, proximal Anastomosis Lyostypt®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>distal and proximal Anastomosis Lyostypt®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>distal and proximal Anastomosis Surgicel®</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lyostypt® AND Surgicel®</intervention_name>
    <description>The investigational products are the hemostats Lyostypt® and Surgicel® (=Tabotamp® ). Lyostypt® will be provided in the size 5cm x 8cm, Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.
Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII.
Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Lyostypt®</other_name>
    <other_name>Surgicel®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lyostypt®</intervention_name>
    <description>The investigational product is the hemostat Lyostypt®. Lyostypt® will be provided in the size 5cm x 8cm. The devices will be cut into half.
Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgicel®</intervention_name>
    <description>The investigational product is the hemostat Surgicel® (=Tabotamp® ). Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.
Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage.</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with an indication for a peripheral vascular reconstruction due to peripheral
             vascular disease (PVD) including femoro-femoral, femoro-popliteal and femoro-crural
             reconstructions or the need of a crossover including femoro-femoral or ilaco-femoro
             reconstruction.

          -  suture hole bleeding of peripheral arterial bypass anastomosis using PTFE graft
             prosthesis

          -  Written informed consent

        Exclusion Criteria:

          -  Emergency surgery

          -  Patients with coagulopathy or uremia

          -  Reoperation within one month at the same location

          -  Pregnant and Breastfeeding Women

          -  Known or suspected allergies or hypersensitivity to any of the used devices (e.g. to
             material of bovine origin)

          -  Severe comorbidity (ASA ≥ 4)

          -  Life expectancy less than 12 months

          -  Current immunosuppressive therapy (more than 40 mg of corticoid per day or
             ezathioprin)

          -  Chemotherapy within last 4 weeks

          -  Radiotherapy on the treated region within the last 2 months

          -  Severe psychiatric or neurologic diseases

          -  Lack of compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hardy Schumacher, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Klinikum Hanau GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Hanau GmbH, Gefaesschirurgie</name>
      <address>
        <city>Hanau</city>
        <state>Hessen</state>
        <zip>63450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Bellón JM, Buján J, Contreras LA, Hernando A, Jurado F. Similarity in behavior of polytetrafluoroethylene (ePTFE) prostheses implanted into different interfaces. J Biomed Mater Res. 1996 May;31(1):1-9.</citation>
    <PMID>8731143</PMID>
  </reference>
  <reference>
    <citation>Carney WI Jr, Lilly MP. Intraoperative evaluation of PTFE, Dacron and autogenous vein as carotid patch materials. Ann Vasc Surg. 1987 Dec;1(5):583-6.</citation>
    <PMID>2974302</PMID>
  </reference>
  <reference>
    <citation>Zdrahala RJ. Small caliber vascular grafts. Part I: state of the art. J Biomater Appl. 1996 Apr;10(4):309-29. Review.</citation>
    <PMID>8859403</PMID>
  </reference>
  <reference>
    <citation>Lumsden AB, Heyman ER; Closure Medical Surgical Sealant Study Group. Prospective randomized study evaluating an absorbable cyanoacrylate for use in vascular reconstructions. J Vasc Surg. 2006 Nov;44(5):1002-1009; discussion 1009. Epub 2006 Oct 3.</citation>
    <PMID>17020801</PMID>
  </reference>
  <reference>
    <citation>Miller CM, Sangiolo P, Jacobson JH 2nd. Reduced anastomotic bleeding using new sutures with a needle-suture diameter ratio of one. Surgery. 1987 Feb;101(2):156-60.</citation>
    <PMID>3810486</PMID>
  </reference>
  <reference>
    <citation>Citrin P, Doscher W, Wise L, Margolis IB. Control of needle hole bleeding with ethyl-cyanoacrylate glue (Krazy Glue). J Vasc Surg. 1985 May;2(3):488-90.</citation>
    <PMID>3999241</PMID>
  </reference>
  <reference>
    <citation>Hait MR, Robb CA, Baxter CR, Borgmann AR, Tippett LO. Comparative evaluation of Avitene microcrystalline collagen hemostat in experimental animal wounds. Am J Surg. 1973 Mar;125(3):284-7.</citation>
    <PMID>4570330</PMID>
  </reference>
  <reference>
    <citation>Hatsuoka M, Seiki M, Sasaki K, Kashii A. Hemostatic effects of microfibrillar collagen hemostat (MCH) in experimental coagulopathy model and its mechanism of hemostasis. Thromb Res. 1986 May 1;42(3):407-12.</citation>
    <PMID>3520941</PMID>
  </reference>
  <reference>
    <citation>Silverstein ME, Keown K, Owen JA, Chvapil M. Collagen fibers as a fleece hemostatic agent. J Trauma. 1980 Aug;20(8):688-94.</citation>
    <PMID>7401211</PMID>
  </reference>
  <reference>
    <citation>Czerny M, Verrel F, Weber H, Müller N, Kircheis L, Lang W, Steckmeier B, Trubel W. Collagen patch coated with fibrin glue components. Treatment of suture hole bleedings in vascular reconstruction. J Cardiovasc Surg (Torino). 2000 Aug;41(4):553-7.</citation>
    <PMID>11052282</PMID>
  </reference>
  <reference>
    <citation>Joseph T, Adeosun A, Paes T, Bahal V. Randomised controlled trial to evaluate the efficacy of TachoComb H patches in controlling PTFE suture-hole bleeding. Eur J Vasc Endovasc Surg. 2004 May;27(5):549-52.</citation>
    <PMID>15079782</PMID>
  </reference>
  <reference>
    <citation>Jackson MR, Gillespie DL, Longenecker EG, Goff JM, Fiala LA, O'Donnell SD, Gomperts ED, Navalta LA, Hestlow T, Alving BM. Hemostatic efficacy of fibrin sealant (human) on expanded poly-tetrafluoroethylene carotid patch angioplasty: a randomized clinical trial. J Vasc Surg. 1999 Sep;30(3):461-6.</citation>
    <PMID>10477639</PMID>
  </reference>
  <reference>
    <citation>Taylor LM Jr, Mueller-Velten G, Koslow A, Hunter G, Naslund T, Kline R; Beriplast B Investigators. Prospective randomized multicenter trial of fibrin sealant versus thrombin-soaked gelatin sponge for suture- or needle-hole bleeding from polytetrafluoroethylene femoral artery grafts. J Vasc Surg. 2003 Oct;38(4):766-71.</citation>
    <PMID>14560228</PMID>
  </reference>
  <reference>
    <citation>Glickman M, Gheissari A, Money S, Martin J, Ballard JL; CoSeal Multicenter Vascular Surgery Study Group. A polymeric sealant inhibits anastomotic suture hole bleeding more rapidly than gelfoam/thrombin: results of a randomized controlled trial. Arch Surg. 2002 Mar;137(3):326-31; discussion 332.</citation>
    <PMID>11888460</PMID>
  </reference>
  <reference>
    <citation>Schonauer C, Tessitore E, Barbagallo G, Albanese V, Moraci A. The use of local agents: bone wax, gelatin, collagen, oxidized cellulose. Eur Spine J. 2004 Oct;13 Suppl 1:S89-96. Epub 2004 Jun 22. Review.</citation>
    <PMID>15221572</PMID>
  </reference>
  <reference>
    <citation>Wachol-Drewek Z, Pfeiffer M, Scholl E. Comparative investigation of drug delivery of collagen implants saturated in antibiotic solutions and a sponge containing gentamicin. Biomaterials. 1996 Sep;17(17):1733-8.</citation>
    <PMID>8866036</PMID>
  </reference>
  <reference>
    <citation>Uranüs, S. ; Pfeifer, J. ; Alimoglu, O. ; Özmen, T. Laparoskopische Eingriffe an der Milz Chir Gastroenterol 2004;20(Suppl.2):35-41 (DOI:10.1159/000083352)</citation>
  </reference>
  <reference>
    <citation>Heidemann D, Hartenstein B. [Effect of local hemostyptics on human gingiva fibroblasts in culture]. Dtsch Z Mund Kiefer Gesichtschir. 1989 May-Jun;13(3):226-9. German.</citation>
    <PMID>2625015</PMID>
  </reference>
  <reference>
    <citation>Haussmann P, Mergard UE, Köhnlein HE. [Effect of various hemostatics. Animal experiment studies]. Fortschr Med. 1974 May 9;92(13):579-80. German.</citation>
    <PMID>4829453</PMID>
  </reference>
  <reference>
    <citation>Bauer P, Köhne K. Evaluation of experiments with adaptive interim analyses. Biometrics. 1994 Dec;50(4):1029-41.</citation>
    <PMID>7786985</PMID>
  </reference>
  <reference>
    <citation>Jensen LP, Lepäntalo M, Fossdal JE, Røder OC, Jensen BS, Madsen MS, Grenager O, Fasting H, Myhre HO, Baekgaard N, Nielsen OM, Helgstrand U, Schroeder TV. Dacron or PTFE for above-knee femoropopliteal bypass. a multicenter randomised study. Eur J Vasc Endovasc Surg. 2007 Jul;34(1):44-9. Epub 2007 Apr 2.</citation>
    <PMID>17400486</PMID>
  </reference>
  <reference>
    <citation>Ballotta E, Renon L, Toffano M, Da Giau G. Prospective randomized study on bilateral above-knee femoropopliteal revascularization: Polytetrafluoroethylene graft versus reversed saphenous vein. J Vasc Surg. 2003 Nov;38(5):1051-5.</citation>
    <PMID>14603216</PMID>
  </reference>
  <reference>
    <citation>Devine C, McCollum C; North West Femoro-Popliteal Trial Participants. Heparin-bonded Dacron or polytetrafluorethylene for femoropopliteal bypass: five-year results of a prospective randomized multicenter clinical trial. J Vasc Surg. 2004 Nov;40(5):924-31.</citation>
    <PMID>15557906</PMID>
  </reference>
  <reference>
    <citation>Eiberg JP, Røder O, Stahl-Madsen M, Eldrup N, Qvarfordt P, Laursen A, Greve M, Flörenes T, Nielsen OM, Seidelin C, Vestergaard-Andersen T, Schroeder TV. Fluoropolymer-coated dacron versus PTFE grafts for femorofemoral crossover bypass: randomised trial. Eur J Vasc Endovasc Surg. 2006 Oct;32(4):431-8. Epub 2006 Jun 27.</citation>
    <PMID>16807001</PMID>
  </reference>
  <reference>
    <citation>Kapfer X, Meichelboeck W, Groegler FM. Comparison of carbon-impregnated and standard ePTFE prostheses in extra-anatomical anterior tibial artery bypass: a prospective randomized multicenter study. Eur J Vasc Endovasc Surg. 2006 Aug;32(2):155-68. Epub 2006 Apr 17.</citation>
    <PMID>16617028</PMID>
  </reference>
  <reference>
    <citation>Klinkert P, Schepers A, Burger DH, van Bockel JH, Breslau PJ. Vein versus polytetrafluoroethylene in above-knee femoropopliteal bypass grafting: five-year results of a randomized controlled trial. J Vasc Surg. 2003 Jan;37(1):149-55.</citation>
    <PMID>12514593</PMID>
  </reference>
  <results_reference>
    <citation>Qerimi B, Baumann P, Hüsing J, Knaebel HP, Schumacher H. Collagen hemostat significantly reduces time to hemostasis compared with cellulose: COBBANA, a single-center, randomized trial. Am J Surg. 2013 Jun;205(6):636-41. doi: 10.1016/j.amjsurg.2012.05.033. Epub 2013 Jan 17.</citation>
    <PMID>23332688</PMID>
  </results_reference>
  <results_reference>
    <citation>Baumann P, Schumacher H, Hüsing J, Luntz S, Knaebel HP. A randomized, controlled, prospective trial to evaluate the haemostatic effect of Lyostypt versus Surgicel in arterial bypass anastomosis: &quot;COBBANA&quot; trial. Trials. 2009 Sep 29;10:91. doi: 10.1186/1745-6215-10-91.</citation>
    <PMID>19788736</PMID>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2009</study_first_submitted>
  <study_first_submitted_qc>February 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2009</study_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PTFE Graft</keyword>
  <keyword>Suture Hole Bleeding</keyword>
  <keyword>Hemostasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

